DiaSorin is an Italy based bio-tech multinational, world leader in the lab diagnostics market, specialized in the immunodiagnostics and molecular diagnostics segments and active in the licensed technology business. It has been developing, producing and marketing reagent kits for laboratory diagnostics all over the world for over 50 years.
Its broad offering of diagnostic tests and licensed technology solutions positions DiaSorin as the market player with the widest range of specialty solutions in the sector.
Listed on the Italian Stock Exchange since 2007, DiaSorin is present on a global scale with 45 companies, 4 branches, 10 production facilities and 9 research and development centres, employing more than 3,300 people and making two thirds of its revenues outside Europe.
In the bio-tech industry, success is based on continuous innovation through major investments in research and development, while scale and global reach are essential. In 2021 DiaSorin acquired the US based Luminex Corporation, listed on the NASDAQ, in an all-cash transaction worth USD1.8 billion that allowed the group to acquire new competencies and gain multiplexing technology for molecular diagnostics.
UniCredit participated into the USD1.6 billion financing package granted by primary financial institutions to DiaSorin in the context of Luminex acquisition, and later acted as joint bookrunner in the placement of senior unsecured equity linked bonds worth €500 million, for a capital market takeout of the financing package.
Piergiorgio Pedron, Chief Financial Officer at DiaSorin